OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, announces the appointments of Mr. Kym Anthony to the position of C.E.O. and Mr. Jeffrey Kraws, a director of the Corporation, to the position of Chairman of the Board. Mr. Anthony previously held the dual role of interim C.E.O. and Chairman. In light of Mr. Anthony’s appointment as Avivagen’s permanent C.E.O. he has stepped down as Chairman but will remain on the board.
Well-known and respected on Wall Street, Mr. Kraws has received some of the most prestigious awards in the industry, including having been consistently ranked among the Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades; as well as previously having been ranked highest for stock performance for pharmaceuticals by Starmine and for estimates by Zacks.
Mr. Kraws is currently CEO of Crystal Research Associates and partner at CRA Advisors. Previously Mr. Kraws served as co-president of The Investor Relations Group (IRG); managing director of healthcare research for Ryan Beck & Co.; and director of research/senior pharmaceutical analyst and managing director at Gruntal & Company. Mr. Kraws has also served as managing director of the healthcare research group and senior pharmaceutical analyst at First Union Securities (formerly EVEREN Securities); as senior U.S. pharmaceutical analyst for the Swedish-Swiss conglomerate Asea Brow Boveri; and as managing director and president of the brokerage/investment banking operation of ABB Aros Securities, Inc. Mr. Kraws has also served as head of competitive analysis within the treasury group at Bristol-Myers Squibb Company.
In addition to serving as CEO of Crystal Research Associates, Mr. Kraws is currently chairman of Synthetic Biologics Inc., a NYSE-listed biotechnology company, a partner and co-founder of TopHat Capital, LLC., president of Ra Medical Systems; an NYSE medical device company, and an Industry Advisor in healthcare investment banking for Piper Jaffray an NYSE listed leading investment bank and investment management firm.
Through his years of experience, Mr. Kraws has cultivated a wealth of industry knowledge and a level of credible, insightful equity analysis that few share. As a result, he has provided guest commentary for many network news programs, including Bloomberg, FOX Business, and CNBC, among others, and has become a valuable resource for financial journalists from the New York Times, Forbes, Bloomberg, CBS MarketWatch, and MedAdNews, among other publications.
Mr. Kraws holds an MBA from Cornell University and a B.S. from State University of New York, Buffalo.
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.
About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colours, and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the United States, Philippines, Taiwan, New Zealand and Thailand.
Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
About Vivamune™ Health Chews (Vivamune™)
Vivamune™ is an all-in-one chew that can dramatically simplify a pet’s supplement routine. Featuring a newly-discovered, novel immune-supporting active ingredient, OxC-beta™, Vivamune™ targets joints, skin and digestive health all in a single, tasty chew a pet will love. Vivamune™ is available for sale in the United States, Canada, Philippines, Taiwan and New Zealand. For more information, visit www.vivamunehealth.com. The contents of the website are expressly not incorporated by reference in this press release.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements regarding the potential for OxC-beta™ Livestock to fulfill the global mandate to remove all in-feed antibiotics as growth promoters are forward looking statements. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds due to many factors, many of which are outside of Avivagen’s control. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright © 2019 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.